Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (571-580 of 713) with videos related to

Pageof 72
Sort By:
British Journal of Cancer|May 17, 2018
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancersJorge Cortes, Kenji Tamura, Daniel J DeAngelo, et al.
Blood|June 29, 2007
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeAndres O Soriano, Hui Yang, Stefan Faderl, et al.
The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.
American Journal of Hematology|December 31, 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapyElias Jabbour, Naval Daver, Richard Champlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
The New England Journal of Medicine|June 16, 2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasMoshe Talpaz, Neil P Shah, Hagop Kantarjian, et al.
Blood|December 7, 2013
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Hagop M Kantarjian, Giuseppe Saglio, et al.
American Journal of Hematology|August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experiencePrajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
Pageof 72

Showing results (571-580 of 713) with videos related to

Sort By:
Pageof 72
British Journal of Cancer|May 17, 2018
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancersJorge Cortes, Kenji Tamura, Daniel J DeAngelo, et al.
Blood|June 29, 2007
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeAndres O Soriano, Hui Yang, Stefan Faderl, et al.
The Lancet. Haematology|March 19, 2018
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trialMaro Ohanian, Ana Tari Ashizawa, Guillermo Garcia-Manero, et al.
American Journal of Hematology|December 31, 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapyElias Jabbour, Naval Daver, Richard Champlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaDeborah A Thomas, Susan O'Brien, Stefan Faderl, et al.
The New England Journal of Medicine|June 16, 2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemiasMoshe Talpaz, Neil P Shah, Hagop Kantarjian, et al.
Blood|December 7, 2013
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)Elias Jabbour, Hagop M Kantarjian, Giuseppe Saglio, et al.
American Journal of Hematology|August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experiencePrajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Blood|May 20, 2006
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetMichele Baccarani, Giuseppe Saglio, John Goldman, et al.
Investigational New Drugs|April 22, 2008
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemiaWendy Stock, Samir D Undevia, Carol Bivins, et al.
Pageof 72